MAPT and Alzheimer disease: Recently, the validity of cerebral organoids as a model for investigating AD disease was further confirmed when AD patient‐derived organoids with either APOE ε3/ ε3 or APOE ε4/ε4 mutations recapitulated increased levels of Aβ and phosphorylated tau (Zhao et al. 2020).